| abstract |
A compound comprising at least two components, a first component being the nLG3 domain from the C-terminus of human agrin, and at least one second component, selected from proteins or an antagonistic antibody that inhibit ActR2B-induced signaling activity in the presence of myostatin, the components being linked by means of linking entities. Such compounds are effective treatments for neuromuscular diseases and problems. |